文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

人类肾细胞癌的代谢组学分析揭示了组织来源在营养供应中的主导地位。

Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.

机构信息

Department of Biology, Massachusetts Institute of Technology, Cambridge, United States.

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, United States.

出版信息

Elife. 2024 May 24;13:RP95652. doi: 10.7554/eLife.95652.


DOI:10.7554/eLife.95652
PMID:38787918
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11126308/
Abstract

The tumor microenvironment is a determinant of cancer progression and therapeutic efficacy, with nutrient availability playing an important role. Although it is established that the local abundance of specific nutrients defines the metabolic parameters for tumor growth, the factors guiding nutrient availability in tumor compared to normal tissue and blood remain poorly understood. To define these factors in renal cell carcinoma (RCC), we performed quantitative metabolomic and comprehensive lipidomic analyses of tumor interstitial fluid (TIF), adjacent normal kidney interstitial fluid (KIF), and plasma samples collected from patients. TIF nutrient composition closely resembles KIF, suggesting that tissue-specific factors unrelated to the presence of cancer exert a stronger influence on nutrient levels than tumor-driven alterations. Notably, select metabolite changes consistent with known features of RCC metabolism are found in RCC TIF, while glucose levels in TIF are not depleted to levels that are lower than those found in KIF. These findings inform tissue nutrient dynamics in RCC, highlighting a dominant role of non-cancer-driven tissue factors in shaping nutrient availability in these tumors.

摘要

肿瘤微环境是癌症进展和治疗效果的决定因素,其中营养物质的可用性起着重要作用。尽管已经确定特定营养物质的局部丰度决定了肿瘤生长的代谢参数,但指导肿瘤与正常组织和血液中营养物质可用性的因素仍知之甚少。为了在肾细胞癌(RCC)中定义这些因素,我们对肿瘤间质液(TIF)、相邻正常肾间质液(KIF)和从患者中采集的血浆样本进行了定量代谢组学和全面脂质组学分析。TIF 的营养组成与 KIF 非常相似,这表明与癌症存在无关的组织特异性因素对营养水平的影响比肿瘤驱动的改变更强。值得注意的是,在 RCC TIF 中发现了与已知 RCC 代谢特征一致的选择代谢物变化,而 TIF 中的葡萄糖水平并未耗尽至低于 KIF 中的水平。这些发现为 RCC 中的组织营养动态提供了信息,突出了非癌症驱动的组织因素在塑造这些肿瘤中营养物质可用性方面的主导作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8611/11126308/1293751668eb/elife-95652-fig2-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8611/11126308/4f5801c227d3/elife-95652-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8611/11126308/e8d3b0fcdc01/elife-95652-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8611/11126308/29a03c878788/elife-95652-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8611/11126308/b68945841a74/elife-95652-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8611/11126308/d1e72cc95992/elife-95652-fig2-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8611/11126308/1293751668eb/elife-95652-fig2-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8611/11126308/4f5801c227d3/elife-95652-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8611/11126308/e8d3b0fcdc01/elife-95652-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8611/11126308/29a03c878788/elife-95652-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8611/11126308/b68945841a74/elife-95652-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8611/11126308/d1e72cc95992/elife-95652-fig2-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8611/11126308/1293751668eb/elife-95652-fig2-figsupp3.jpg

相似文献

[1]
Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.

Elife. 2024-5-24

[2]
Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.

bioRxiv. 2024-4-8

[3]
The Black Book of Psychotropic Dosing and Monitoring.

Psychopharmacol Bull. 2024-7-8

[4]
Short-Term Memory Impairment

2025-1

[5]
Management of urinary stones by experts in stone disease (ESD 2025).

Arch Ital Urol Androl. 2025-6-30

[6]
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.

Elife. 2025-5-23

[7]
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].

Epidemiol Prev. 2013

[8]
Home treatment for mental health problems: a systematic review.

Health Technol Assess. 2001

[9]
Sexual Harassment and Prevention Training

2025-1

[10]
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.

Clin Orthop Relat Res. 2025-1-1

引用本文的文献

[1]
Tumour interstitial fluid-enriched phosphoethanolamine suppresses T cell function.

Nat Cell Biol. 2025-5

[2]
Arginine: at the crossroads of nitrogen metabolism.

EMBO J. 2025-3

[3]
La dolce vita: fueling chimeric antigen receptor (CAR) T cells with Glut1 to improve therapeutic efficacy.

Immunometabolism (Cobham). 2025-1-13

[4]
Site of breast cancer metastasis is independent of single nutrient levels.

bioRxiv. 2024-10-25

[5]
Identifying metabolic limitations in the tumor microenvironment.

Sci Adv. 2024-10-4

本文引用的文献

[1]
Spatially resolved metabolomics and isotope tracing reveal dynamic metabolic responses of dentate granule neurons with acute stimulation.

Nat Metab. 2023-10

[2]
Screening in serum-derived medium reveals differential response to compounds targeting metabolism.

Cell Chem Biol. 2023-9-21

[3]
Tumor interstitial fluid analysis enables the study of microenvironment-cell interactions in cancers.

Curr Opin Biotechnol. 2023-10

[4]
Pancreatic tumors exhibit myeloid-driven amino acid stress and upregulate arginine biosynthesis.

Elife. 2023-5-31

[5]
Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer.

Nature. 2023-4

[6]
Dynamic partitioning of branched-chain amino acids-derived nitrogen supports renal cancer progression.

Nat Commun. 2022-12-20

[7]
In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma.

Sci Adv. 2022-12-16

[8]
Analyzing cell-type-specific dynamics of metabolism in kidney repair.

Nat Metab. 2022-9

[9]
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.

Clin Cancer Res. 2022-8-2

[10]
Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal -Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect.

JCO Precis Oncol. 2017-5-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索